Skincare and cosmeceutical claims now outnumber the trials that test them. That imbalance frames a new HCPLive discussion aimed at practicing dermatologists.

What makes a cosmeceutical claim credible?

A claim earns weight when it points to an active, a concentration, and an outcome measured in skin, not in surveys. Editors at Dermatology Times and JAAD treat those three elements as a unit. Drop any one, and the claim slides into anecdote.

Dermatologists reading product inserts should ask four quick questions. Does the label list the ingredient by INCIAN name and a vehicle? Does it cite a concentration, and is that concentration inside the range tested in published studies? Does it name a clinical endpoint, such as lesion counts, melanin index, or a validated severity score? Does it separate in-vitro data from human data?

• Active identified? Check INCIAN nomenclature.
• Concentration disclosed? Compare to peer-reviewed ranges.
• Endpoint clinical? Look for human skin, not cell lines.
• Evidence class stated? Rank randomized data above case series.

A "yes" across all four usually signals a claim worth repeating to a patient. A single "no" should slow the conversation.

How should dermatologists frame the conversation with patients?

Marketing language travels faster than data. A moisturizer can call itself "dermatologist tested" after one panel of twenty people. Patients hear a stamp of approval that the trial never earned. The clinical job is to translate. Put the active on the counter. Show the concentration. Hand the patient the study, when one exists.

This is also where coding, reimbursement, and access realities matter. A prescription retinoid with Level I evidence may cost more out of pocket than a cosmeceutical alternative with Level III support. The honest answer names the trade-off in dollars per month, not in vague promises.

What should editors and readers take away?

The takeaway is plain. Sort every cosmeceutical claim by active, concentration, endpoint, and evidence class. If a product cannot answer those four questions, the dermatologist should say so, on the record, in the room. Forward guidance from the field points to a tighter standard: products that disclose data rise, and products that hide behind adjectives fall.